Biogen Stock: What Are The Prospects And Is It Worth Buying

olegas Jul 23, 2021/6 Views Good things come to those who wait. Biotech giant Biogen (NASDAQ: BIIB) can attest to this wisdom. After a long and difficult journey, the company finally received FDA approval for its Alzheimer’s disease (AD) drug, Aduhelm. The regulator went against the will of an independent commission, which strongly opposed the drug’s approval back in November 2020. This…